Neuland Laboratories Ltd

Neuland Laboratories Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 September 2026, providing investors with the latest insights into its performance and outlook.

With a remarkable 65.64% gain over the past year, Neuland Laboratories Ltd surged to a fresh 52-week and all-time high of Rs 24,235.05 on 09 Sep 2026, defying the broader market's subdued tone and showcasing robust technical momentum across multiple timeframes.

Extending its remarkable ascent, Neuland Laboratories Ltd touched a fresh all-time high of Rs 24,183.45 on 09 Sep 2026, marking a significant milestone in its long-term rally that has outpaced the broader market by a wide margin.

With a remarkable surge to Rs 23,947.15 on 8 Sep 2026, Neuland Laboratories Ltd has reached a fresh 52-week and all-time high, extending its impressive 65.38% return over the past year. This milestone comes amid a broader market environment where the Sensex has been under pressure, highlighting the stock's distinct momentum and technical resilience.

Neuland Laboratories Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by touching an all-time high price of Rs.23,947.15 on 08 Sep 2026. This achievement reflects the company’s robust financial performance and sustained growth trajectory over recent years.

Neuland Laboratories Ltd has demonstrated a notable shift in technical momentum, upgrading its trend from mildly bullish to bullish. This change is supported by a confluence of positive signals across key technical indicators including MACD, Bollinger Bands, and moving averages, suggesting a strengthening price trajectory amid a robust fundamental backdrop.

Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. This transition is underscored by mixed signals from key technical indicators such as MACD, RSI, moving averages, and others, suggesting a cautious but optimistic outlook for investors as the stock navigates near its 52-week high.

Neuland Laboratories Ltd has exhibited a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend, supported by strong signals from key indicators such as MACD, Bollinger Bands, and moving averages. This technical evolution, coupled with robust long-term returns, positions the small-cap pharmaceutical firm favourably amid a challenging market backdrop.

Neuland Laboratories Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance. This transition is underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages, suggesting a cautious yet optimistic outlook for investors as the stock continues to outperform the broader market benchmarks.

Neuland Laboratories Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall market stance.

With a remarkable 70.19% gain over the past year, Neuland Laboratories Ltd surged to a fresh 52-week and all-time high of Rs 23,899 on 21 Aug 2026, outpacing the Sensex which declined by 5.46% over the same period. This milestone reflects a powerful technical momentum that has propelled the stock well above its key moving averages, signalling sustained bullishness in the pharmaceuticals sector.

Neuland Laboratories Ltd has reached a significant milestone by touching its all-time high price of Rs. 23,899 on 21 August 2026, reflecting a remarkable journey of sustained growth and robust financial performance within the Pharmaceuticals & Biotechnology sector.

Neuland Laboratories Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 01 June 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 18 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Surging to a new all-time peak of Rs 23,850 on 18 Aug 2026, Neuland Laboratories Ltd has demonstrated remarkable price momentum, outpacing the broader market with a 74.34% gain over the past year against the Sensex’s decline of 4.71%. This milestone caps a sustained rally fuelled by a confluence of bullish technical indicators and robust quarterly earnings growth.

Neuland Laboratories Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by touching its all-time high price of Rs.23,850 on 18 Aug 2026. This achievement reflects the company’s robust financial performance and sustained growth trajectory over recent years.

Surging to a new all-time peak of Rs 23,753.45 on 17 Aug 2026, Neuland Laboratories Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a declining Sensex. This milestone caps a 78.79% rally over the past year, underscoring the stock’s robust technical positioning and sustained upward trajectory.

Neuland Laboratories Ltd has reached a significant milestone by touching its all-time high price of ₹23,650 on 17 August 2026, reflecting a remarkable journey of sustained growth and robust financial performance within the Pharmaceuticals & Biotechnology sector.